SCHEMBL626542

SCHEMBL626542

CC(=O)Nc1cc(-c2cc(-c3ncn(COCC[Si](C)(C)C)n3)c(-c3cc(CN4CCCC4)ccc3Cl)o2)c(C)cn1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.33
HSP90AB1 P08238 3/20 0.33
KLKB1 P03952 1/20 0.33
GAA P10253 1/20 0.33
WDR5 P61964 1/20 0.33
F10 P00742 3/20 0.32
HRH3 Q9Y5N1 1/20 0.32
DGAT1 O75907 1/20 0.32
SSTR5 P35346 3/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ABL1 P00519 1/20 0.32
CCR3 P51677 1/20 0.31
AURKA O14965 1/20 0.31
AURKB Q96GD4 1/20 0.31
WNT1 P04628 1/20 0.31
GSK3B P49841 1/20 0.31
DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623168 0.86
SCHEMBL15051198 0.84 WDR5 (0.34) KLKB1GAAWDR5F10HRH3
SCHEMBL15051384 0.79 DGAT1 (0.34) KLKB1GAAF10HRH3DGAT1
SCHEMBL626550 0.79
SCHEMBL15072595 0.78 DGAT1 (0.34) KLKB1GAAF10HRH3DGAT1
SCHEMBL9108830 0.77 KDM4E (0.36) HSP90AA1HSP90AB1GAAWDR5F10
SCHEMBL624381 0.74 CSNK2A2 (0.31)
SCHEMBL15050849 0.74 KLKB1 (0.34) KLKB1GAAHRH3
SCHEMBL627869 0.72
SCHEMBL626227 0.71 DGAT1 (0.31) DGAT1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
EP-2603216-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2013-06-19 EP disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2012021615-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
WO-2012021615-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 HSP90AA1 413/4885HSP90AB1 133/4885KLKB1 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.